Wenhui Guo - Publications

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 03, 2026

Identification of two genes associated with recurrence in Paget's disease and construction of a predictive model.

Journal: Frontiers in genetics

Published: January 09, 2026

Impact of COVID-19 on neoadjuvant chemotherapy efficacy in patients with breast cancer: An ambidirectional cohort study and mendelian randomization analysis.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: July 04, 2025

Feasibility and accuracy of targeted axillary dissection by carbon tattooing in biopsy-proven node-positive breast cancer: A prospective study.

Journal: Cancer

Published: March 27, 2025

Prognostic value of nuclear features based on tumor-associated collagen signatures in breast cancer.

Journal: NPJ breast cancer

Published: March 25, 2025

Dynamic tumor-infiltrating lymphocytes predicts survival in HR+/HER2- early breast cancer: a pre-to-post neoadjuvant chemotherapy study.

Journal: Breast cancer research : BCR

Published: March 16, 2025

Timing of surgery and 1-year postoperative outcomes in patients with breast cancer and preoperative COVID-19 history: A matched, longitudinal, ambidirectional cohort study.

Journal: International journal of cancer

Published: November 08, 2024

Effect of a machine learning prediction model on the false-negative rate of sentinel lymph node biopsy for clinically node-positive breast cancer after neoadjuvant chemotherapy.

Journal: Breast (Edinburgh, Scotland)

Published: September 08, 2024

Frequency of somatic and germline variants of predisposition genes in young Chinese women with breast cancer.

Journal: Breast cancer research and treatment

Published: August 19, 2024

Identification of sequence polymorphism in the D-loop region of mitochondrial DNA as a risk factor for breast cancer.

Journal: Cancer science

Published: April 01, 2024

Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China.

Journal: Journal of cancer research and clinical oncology

Published: February 12, 2024

Clinical TP53 genetic testing is recommended for HER2-positive breast cancer patients aged 35 or younger.

Journal: NPJ genomic medicine

Published: February 10, 2024